相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants
Shuai Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Late-Stage Pancreatic Cancer Detected During High-Risk Individual Surveillance: A Systematic Review and Meta-Analysis
Ankit Chhoda et al.
GASTROENTEROLOGY (2022)
Timeline of Development of Pancreatic Cancer and Implications for Successful Early Detection in High-Risk Individuals
Kasper A. Overbeek et al.
GASTROENTEROLOGY (2022)
Germline Sequencing DNA Repair Genes in 5545 Men With Aggressive and Nonaggressive Prostate Cancer
Burcu F. Darst et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021
Mary B. Daly et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Prostate Cancer, Version 1.2021 Featured Updates to the NCCN Guidelines
Edward Schaeffer et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
Andrew N. J. Tutt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Risk of colorectal cancer associated with BRCA1 and/or BRCA2 mutation carriers: systematic review and meta-analysis
C. M. Cullinane et al.
BRITISH JOURNAL OF SURGERY (2020)
Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)
Valentina Silvestri et al.
JAMA ONCOLOGY (2020)
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration
Wassim Abida et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Genetic characterization of pancreatic cancer patients and prediction of carrier status of germline pathogenic variants in cancer-predisposing genes
Keijiro Mizukami et al.
EBIOMEDICINE (2020)
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial
J. K. Litton et al.
ANNALS OF ONCOLOGY (2020)
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
M. E. Robson et al.
ANNALS OF ONCOLOGY (2019)
RE: BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-analysis
Bryson W. Katona et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Talia Golan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers
Elizabeth C. Page et al.
EUROPEAN UROLOGY (2019)
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
A. Gonzalez-Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Breast Cancer Screening in High-Risk Men: A 12-year Longitudinal Observational Study of Male Breast Imaging Utilization and Outcomes
Yiming Gao et al.
RADIOLOGY (2019)
Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma
Peter A. Johansson et al.
MELANOMA RESEARCH (2019)
Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance
Marcia Irene Canto et al.
GASTROENTEROLOGY (2018)
Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms
Maeve A. Lowery et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms
Maeve A. Lowery et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-analysis
Mok Oh et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
K. Moore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Accuracy of self-reported family history of cancer, mutation status and tumor characteristics in patients with early onset breast cancer
Annelie Augustinsson et al.
ACTA ONCOLOGICA (2018)
Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results
Mary Pritzlaff et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Linking uterine serous carcinoma to BRCA1/2-associated cancer syndrome: A meta-analysis and case report
M. M. de Jonge et al.
EUROPEAN JOURNAL OF CANCER (2017)
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
Karoline B. Kuchenbaecker et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman et al.
LANCET (2017)
Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers
Hans Vasen et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Bella Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
J. Mateo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Cancers Associated With BRCA1 and BRCA2 Mutations Other Than Breast and Ovarian
Jacqueline Mersch et al.
CANCER (2015)
Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients: results from a collaborative multicenter study in Italy
Laura Ottini et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations
A. Moran et al.
FAMILIAL CANCER (2012)
Risk of breast cancer in male BRCA2 carriers
D. G. R. Evans et al.
JOURNAL OF MEDICAL GENETICS (2010)
Accuracy of self-reported family history of cancer in a large case-control study of ovarian cancer
Marie Soegaard et al.
CANCER CAUSES & CONTROL (2008)
Breast cancer risk among male BRCA1 and BRCA2 mutation carriers
Yu Chuan Tai et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: A kin-cohort study in Ontario, Canada
Harvey A. Risch et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Cancer risks in BRCA2 families:: estimates for sites other than breast and ovary
CJ van Asperen et al.
JOURNAL OF MEDICAL GENETICS (2005)
Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history
HJ Murff et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
BRCA1 and BRCA2 mutations in a population-based study of male breast cancer
VM Basham et al.
BREAST CANCER RESEARCH (2002)
Variation in cancer risks, by mutation position, in BRCA2 mutation carriers
D Thompson et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2001)
分享论文
